Markus Raderer

Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.

Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT-Lymphoma) of the Intestine: A Single Center Analysis.

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.

Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms.

Deep learning for [18F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis

Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.

ABO blood group type and risk of venous thromboembolism in patients with cancer.

Imaging Inflammation in Atherosclerosis with CXCR4-Directed [⁶⁸Ga]PentixaFor PET/MRI-Compared with [¹⁸F]FDG PET/MRI.

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna.

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).

Thyroid MALT lymphoma: self-harm to gain potential T-cell help.

Management of adrenocortical carcinoma: are we making progress?

Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.

What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments.

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria.

Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).

First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna.

Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna.

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.

Significant association between <i>TNFAIP3</i> inactivation and biased immunoglobulin heavy chain variable region 4‐34 usage in mucosa‐associated lymphoid tissue lymphoma

Proceedings of the International Cancer Imaging Society (ICIS) 16th Annual Teaching Course

A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)